CFOs of early-stage biotechnology firms get a lot of practice in the art of raising money. No matter the market cycle, they must find capital to fund costly research that will ideally lead to new drugs or treatments that generate revenue — and turn them cash-flow positive. Finance chiefs at pre-revenue companies must tamp down cash-burn as […]

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with topline data expected in the fourth quarter of 2023. “We believe REN001 is a pipeline in a pill to treat a host of diseases involved […]

If there’s one overarching theme that investors in biotech stocks should pay attention to in 2023, it’s “genetic medicine, genetic medicine, genetic medicine,” says Christopher Anzalone. Anzalone is biased, of course. He’s the chief executive of Arrowhead Pharmaceuticals (ARWR), a leader in a technology known as RNA interference, which turns off problem genes at the center of […]